Integrating Multisource Target Evidence with Machine-Learning Potency Prediction for Alzheimer's Disease Drug Discovery

Alzheimer's disease (AD) target evidence is distributed across biological, chemical, structural, regulatory, and trial-registry sources, complicating reproducible target evaluation and modeling.

By Pan, Zhai, Lee +3Oct 20, 2026

Score█████░░░░░4.5

Caveats

Not randomized: its findings are associations.
Preprint; not yet peer reviewed.

VerdictWorth a reader's time today.

Read the original PDF

Abstract

Alzheimer's disease (AD) target evidence is distributed across biological, chemical, structural, regulatory, and trial-registry sources, complicating reproducible target evaluation and modeling. We developed a traceable data-to-model platform that integrates AGORA-centered evidence through Target Explorer, Drug-Target Lookup, and Model Portfolio workspaces. The resource contains 967 targets, 452,249 compounds, and 1,430,260 measurements. On a curated PIK3CA dataset, target-specific fine-tuning of the Boltz-2 affinity head increased Pearson r from 0.248 to 0.560 and reduced mean absolute error from 0.900 to 0.706 on 469 held-out compounds. Separately, we screened 42 regression models over 50 random splits for ten moderate-sized target datasets; a random forest model for XDH achieved the highest mean R^2 (0.815). The platform connects curated evidence, model-ready datasets, reproducible evaluation, and public results while clearly separating contextual evidence from therapeutic claims and random-split performance from generalization to unseen chemical scaffolds.

A. Pan, T. Zhai, J. Lee, C. Zheng, D. Kim, L. Shen

The editor's rubric

Heuristic review

Leverage4 / 5: A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).; 24% of this desk’s rubric
Magnitude2 / 5: Solid incremental gain on a meaningful problem.; 16% of this desk’s rubric
Evidence3 / 5: Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.; 20% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 20% of this desk’s rubric
Trajectory3 / 5: A clear path to scale.; 10% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 10% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	████░ 4	24%	A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).
Magnitude	██░░░ 2	16%	Solid incremental gain on a meaningful problem.
Evidence	███░░ 3	20%	Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
Novelty	██░░░ 2	20%	A new combination of known ideas.
Trajectory	███░░ 3	10%	A clear path to scale.
Stakes	███░░ 3	10%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (generalizes, many tasks, programmable); novelty (discovery); verification (multiple benchmarks, held-out test, independent replication); stakes (major disease, prevention or cure). Red flags: not randomized.

How the score was computed

rank-2026-10-18

Score█████░░░░░4.5

Score = 10 × (75% × adjusted merit / 10 + 15% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 5.8 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.8 / 10; Shrunk toward the desk prior by editor confidence (48%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 88%; Half-life decay since publication.

No attention signals recorded yet.

The record

Reviewed by heuristic-v7 on Oct 21, 2026, 05:48 UTC. Paper type: clinical.
Categories: bioinformatics
TOP, No.3 in the Front page edition of October 21, 2026.
BRIEF, No.4 in the Medicine edition of October 21, 2026.
TOP, No.2 in the Biology edition of October 21, 2026.